Logo image
Se connecter
Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children
Article de revue   Avec comité de lecture

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

Marie-Louise Frémond, Mathieu Paul Rodero, Nadia Jeremiah, Alexandre Belot, Eric Jeziorski, Darragh Duffy, Didier Bessis, Guilhem Cros, Gillian I. Rice, Bruno Charbit, …
Journal of allergy and clinical immunology, Vol.138(6), pp.1752-1755
01/12/2016
PMID: 27554814

Résumé

Bacteriology Immunology Life Sciences Microbiology and Parasitology Virology

Indicateurs

1 Consultations de la notice

Détails

Logo image